Although the main focus in Alzheimer's disease (AD) has been an investigation of mechanisms causing Aβ plaque deposition and tau tangle formation, recent studies have shown that phosphorylated TDP-43 pathology is present in up to 50% of sporadic cases. Furthermore, elevated phosphorylated TDP-43 has been associated with more severe AD pathology. Therefore, we hypothesized that TDP-43 may regulate amyloid-beta precursor protein (APP) trafficking and tau phosphorylation/aggregation. In order to examine the role of TDP-43 in AD, we developed a transgenic mouse that overexpresses hippocampal and cortical neuronal TDP-43 in a mouse expressing familial mutations (K595N and M596L) in APP and presenilin 1 (PSEN1ΔE9). In our model, increased TDP-43 was related to increased tau aggregation as evidenced by thioflavin S-positive phosphorylated tau, which may implicate TDP-43 expression in pre-tangle formation. In addition, there was increased endosomal/lysosomal localization of APP and reduced Aβ plaque formation with increased TDP-43. Furthermore, there was decreased calcineurin with elevated TDP-43 expression. Since calcineurin is a phosphatase for TDP-43, the decreased calcineurin expression may be one mechanism leading to an increase in accumulation of diffuse phosphorylated TDP-43 in the hippocampus and cortex. We further show that when TDP-43 is knocked down there is an increase in calcineurin. In our model of selective TDP-43 overexpression in an APP/PSEN1 background, we show that TDP-43 decreases Aβ plaque deposition while increasing abnormal tau aggregation. These observations indicate that TDP-43 may play a role in regulating APP trafficking and tau aggregation. Our data suggest that TDP-43 could be a putative target for therapeutic intervention in AD affecting both Aβ plaque formation and tauopathy.
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Introduction
Alzheimer's disease is the most frequent form of dementia, accounting for 70 to 80% of all cases. The greatest risk factor for AD is aging; an estimated 30 million people are living with AD and over the next 30 years it is projected to increase to over 130 million worldwide (Dolgin, 2016) . In addition, one in three seniors dies with AD or another dementing disease and since 2000, deaths from AD have increased 89% (see 2017 Alzheimer's Disease Facts and Figures, Alzheimer's Association, 2017). The pathology of AD consists of extracellular amyloid-beta (Aβ) plaques and intraneuronal aggregates of the microtubule-associated protein tau (MAPT), which is hyperphosphorylated in neurofibrillary tangles (NFTs) and neuritic plaques (NPs). In APP/ PSEN1 mice, secreted Aβ monomers produced from APP processing disrupt cognitive function, yet there is little or no NFT or NP formation, synaptic loss or neurodegeneration (Abdul et al., 2008; Borchelt et al., 1997; Walsh et al., 2002) . Moreover, there are over a hundred transgenic AD models that have been developed exhibiting either Aβ plaque pathogenesis, NFT formation, neuronal loss or cognitive deficits, but only one of which, the APPSwDI/NOS2 −/− mouse, induces endogenous tauopathy (Colton et al., 2008; Wilcock et al., 2008) .
Although the main focus in AD research has been the investigation of mechanisms associated with Aβ and tau aggregation, recent studies have shown that in up to 50% of late-onset, sporadic cases of AD TDP-43 proteinopathy has been reported as an age-related comorbidity (Amador-Ortiz et al., 2007; Arai et al., 2009; Higashi et al., 2007; Jellinger, 2008; Lippa et al., 2009; Uryu et al., 2008) . TDP-43 functions as a heterogeneous nuclear ribonucleoprotein (hnRNP), with two RNA recognition motifs, nuclear localization and export signals, and a glycine-rich domain involved in protein-protein interactions. TDP-43 participates in exon skipping, RNA stability, RNA transport, splicing, translation, micro-RNA processing, and other cellular functions (Buratti et al., 2010; Buratti et al., 2001; Strong et al., 2007; Wang et al., 2004) . Similar to tau, pathological TDP-43 becomes hyper- 
